ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 639

African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup

Michelle Petri1 and Jessica Li 1, 1Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: African-Americans and proteinuria, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether the difference in frequency was just at the time of SLE diagnosis.

Methods: 1849 SLE patients were included in this analysis. The patients were 93% female, 39.3% African-American and 60.7% Caucasian. 478 patients (27.2%, 271/997 African-American and 15.6%, 207/1330 Caucasian) who had proteinuria before or at the date of diagnosis (± 1 month) were excluded.

Results: The Kaplan-Meier curve of time to first proteinuria (in those without proteinuria at diagnosis) is shown in Figure 1. The separation between African-Americans and Caucasians starts almost immediately after diagnosis and continues to widen until year 30. Although it appears to level off at year 30, that is likely due to smaller numbers remaining in the cohort. Table 1 shows the estimated risk of proteinuria after diagnosis. The estimated probability of having proteinuria within 5 year is 26% for African-American patients and 14% for Caucasian patients. Risk accumulates even 5 years after diagnosis. Table 2 shows the hazard ratio for proteinuria after diagnosis. The risk of proteinuria is 2.19 times higher among African-American patients compared to Caucasians in the unadjusted model. After adjustment for age at diagnosis and gender, the risk remains 2.14 higher for African-Americans compared to Caucasians.

Conclusion: The increased risk of lupus nephritis in African-Americans is not limited to diagnosis or even to the first five years after diagnosis. Increased risk is present through 30 years after diagnosis. As these data also show continued risk in Caucasians, monitoring the urine protein/cr at every follow up visit is recommended for all SLE patients.


ACR 2019-AA risk of proteinuria after diagnosis-Figure1

Figure 1 – Time to First Proteinuria for African-Americans -B- and Caucasians -W-


ACR 2019-AA risk of proteinuria after diagnosis-Table1

Table 1 – Risk of proteinuria after SLE diagnosis


ACR 2019-AA risk of proteinuria after diagnosis-Table2

Table 2 – Hazard Ratio for Proteinuria After Diagnosis – African-American vs Caucasian


Disclosure: M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5; J. Li, None.

To cite this abstract in AMA style:

Petri M, Li J. African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/african-american-risk-of-proteinuria-after-sle-diagnosis-increases-throughout-thirty-years-of-followup/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/african-american-risk-of-proteinuria-after-sle-diagnosis-increases-throughout-thirty-years-of-followup/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology